Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

David G Coffey,Keren Osman,Adolfo Aleman,Selma Bekri,Simone Kats,Amishi Dhadwal,Donna Catamero,Seunghee Kim-Schulze,Sacha Gnjatic,Ajai Chari,Samir Parekh,Sundar Jagannath,Hearn Jay Cho

DOI: https://doi.org/10.1136/jitc-2023-008110

IF: 12.469

2024-04-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Autologous stem cell transplantation (ASCT) after induction therapy improves disease-free survival for patients with multiple myeloma (MM). While the goal of ASCT is to render a minimal disease state, it is also associated with eradication of immunosuppressive cells, and we hypothesize that early introduction of immunotherapy post-ASCT may provide a window of opportunity to boost treatment efficacy. Methods We conducted a phase 1 clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after ASCT in patients with newly diagnosed MM previously treated with induction therapy. In addition to CD34+ stem cells, peripheral blood mononuclear cells were harvested prior to transplant and infused on day 3 after stem cell infusion to accelerate immune reconstitution and provide autologous natural killer (NK) cells that are essential to the mechanism of elotuzumab. Elotuzumab was administered starting on day 4 and then every 28 days after until 1 year post-ASCT. Cycles 4–12 were administered with standard-of-care lenalidomide maintenance. Results All subjects were evaluated for safety, and 13 of 15 subjects completed the treatment protocol. At 1 year post-ASCT, the disease status of enrolled subjects was as follows: five stringent complete responses, one complete response, six very good partial responses, one partial response, and two progressive diseases. The treatment plan was well tolerated, with most grade 3 and 4 AEs being expected hematologic toxicities associated with ASCT. Correlative analysis of the immune microenvironment demonstrated a trend toward reduced regulatory T cells during the first 3 months post-transplant followed by an increase in NK cells and monocytes in patients achieving a complete remission. Conclusions This phase 1 clinical trial demonstrates that early introduction of immunotherapy after ASCT is well tolerated and shows promising disease control in patients with MM, accompanied by favorable changes in the immune microenvironment. Trial registration number NCT02655458 .

oncology,immunology

What problem does this paper attempt to address?

This paper mainly discusses the treatment strategy for Multiple Myeloma (MM). The researchers conducted a phase 1 clinical trial to assess the safety and efficacy of combining anti-SLAMF7 monoclonal antibody (elotuzumab) and autologous lymphocyte infusion after autologous stem cell transplantation (ASCT). In the trial, patients received induction therapy, followed by ASCT, and subsequently received elotuzumab and lenalidomide maintenance therapy.

Fifteen newly diagnosed multiple myeloma patients participated in this study, and the results showed that most patients tolerated the treatment regimen well, and disease control was encouraging. One year later, the patients' disease status included stringent complete response, complete response, very good partial response, and partial response. The side effects of the treatment plan were mainly expected hematologic toxicities related to ASCT.

Through related analysis of the immune microenvironment, the researchers observed a reduction in immune suppressive cells and an increase in natural killer (NK) cells and monocytes in the initial few months after transplantation, which was particularly evident in patients achieving complete response. These findings suggest that early introduction of immune therapy after ASCT may enhance treatment efficacy and improve the immune microenvironment.

Overall, this study demonstrates that the early application of immune therapy after ASCT is feasible, well-tolerated, and may improve disease control in Multiple Myeloma patients. Future research may further explore how this strategy affects patients' survival rates and immune responses.